JP2015501822A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501822A5
JP2015501822A5 JP2014546468A JP2014546468A JP2015501822A5 JP 2015501822 A5 JP2015501822 A5 JP 2015501822A5 JP 2014546468 A JP2014546468 A JP 2014546468A JP 2014546468 A JP2014546468 A JP 2014546468A JP 2015501822 A5 JP2015501822 A5 JP 2015501822A5
Authority
JP
Japan
Prior art keywords
lipocalin mutein
pharmaceutical composition
mutein
composition according
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014546468A
Other languages
English (en)
Japanese (ja)
Other versions
JP6305345B2 (ja
JP2015501822A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/075135 external-priority patent/WO2013087654A2/en
Publication of JP2015501822A publication Critical patent/JP2015501822A/ja
Publication of JP2015501822A5 publication Critical patent/JP2015501822A5/ja
Application granted granted Critical
Publication of JP6305345B2 publication Critical patent/JP6305345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014546468A 2011-12-12 2012-12-12 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 Expired - Fee Related JP6305345B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161569501P 2011-12-12 2011-12-12
US61/569,501 2011-12-12
US201261599152P 2012-02-15 2012-02-15
US61/599,152 2012-02-15
PCT/EP2012/075135 WO2013087654A2 (en) 2011-12-12 2012-12-12 Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018039343A Division JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Publications (3)

Publication Number Publication Date
JP2015501822A JP2015501822A (ja) 2015-01-19
JP2015501822A5 true JP2015501822A5 (OSRAM) 2016-02-04
JP6305345B2 JP6305345B2 (ja) 2018-04-04

Family

ID=47552958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546468A Expired - Fee Related JP6305345B2 (ja) 2011-12-12 2012-12-12 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法
JP2018039343A Pending JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018039343A Pending JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Country Status (9)

Country Link
US (3) US9610356B2 (OSRAM)
EP (2) EP2791684B1 (OSRAM)
JP (2) JP6305345B2 (OSRAM)
CN (1) CN103998937A (OSRAM)
AU (1) AU2012350654C1 (OSRAM)
CA (1) CA2858959A1 (OSRAM)
DK (1) DK2791684T3 (OSRAM)
SG (2) SG11201402996WA (OSRAM)
WO (1) WO2013087654A2 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105168209A (zh) * 2015-09-21 2015-12-23 浙江大学 HDAC1抑制剂在制备调控hepcidin表达药物中的应用
CN105726543A (zh) * 2016-02-22 2016-07-06 浙江大学 腺嘌呤在制备调控hepcidin表达药物中的应用
EP3438282A4 (en) 2016-03-29 2020-05-06 Advanced Telecommunications Research Institute International METHOD FOR SCREENING CANDIDATE SUBSTANCES FOR AN ACTIVE COMPONENT TO PREVENT OR TREAT AT LEAST ONE SELECTED DISEASE IN THE KIDNEY HYPOFUNCTION GROUP, CHRONIC KIDNEY DISEASE AND KIDNEY DEFICIENCY
MA46046A (fr) * 2016-08-29 2019-07-03 Regeneron Pharma Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
WO2020201038A1 (en) 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
EP2498096A1 (en) 2006-07-21 2012-09-12 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
US8629250B2 (en) 2007-02-02 2014-01-14 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
PE20091261A1 (es) 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
EP2803675A3 (en) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
UA103032C2 (uk) 2008-08-06 2013-09-10 Елі Ліллі Енд Компані Селективні антитіла проти гепсидину-25 та їх застосування
WO2010033847A1 (en) 2008-09-18 2010-03-25 The Trustees Of Columbia University In The City Of New York Ngal-binding siderophores and use thereof to treat iron deficiency and iron overload
MA33210B1 (fr) * 2009-03-25 2012-04-02 Genentech Inc Nouveaux anticorps anti-a5b1 et leurs utilisations
CA2798713A1 (en) * 2010-05-10 2011-11-17 Intrinsic Lifesciences Llc Markers for acute kidney injury
ES2667066T3 (es) * 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
EP3299386A1 (en) * 2010-08-16 2018-03-28 Pieris Pharmaceuticals GmbH Binding proteins for hepcidin

Similar Documents

Publication Publication Date Title
JP2015501822A5 (OSRAM)
JP7544932B2 (ja) 抗体含有製剤
Xiao et al. Lipocalin 2: an emerging player in iron homeostasis and inflammation
US20250109183A1 (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
JP6305345B2 (ja) 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法
JP6552636B2 (ja) 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン
ES2424242T3 (es) Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
JP7395479B2 (ja) 免疫抑制なしにil-6媒介性炎症を処置する方法
KR102416078B1 (ko) 항체 함유 제제
JP2014519484A (ja) TNFR:Fc融合タンパク質の安定した医薬液剤
WO2017191437A1 (en) Methods, regimens, combinations & antagonists
JP2023538533A (ja) 線維症の処置のための、ccr2/5拮抗剤と組み合わせたfgf21
US20140348848A1 (en) Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
JP7697959B2 (ja) Il-2タンパク質とcd80タンパク質を含む融合タンパク質製剤
JP2020518658A (ja) 癌治療用ペプチド
KR20180031775A (ko) 긴 반감기 응집 복합체와 관련된 방법 및 조성물
JP6578546B2 (ja) Lt阻害4価ペプチドおよびetec感染症治療薬